國內首個新冠疫苗專利

Patent to COVID-19 vaccine
國內首個新冠疫苗專利

China has granted its first COVID-19 vaccine patent to the adenovirus vector vaccine developed by Chen Wei of the Academy of Military Medical Sciences and Chinese biotech company CanSino Biologics, according to the National Intellectual Property Administration.
據國家知識產權局消息，由軍事醫學研究院陳薇及我國生物科技公司康希諾生物聯合申報的腺病毒載體新冠疫苗專利申請近日獲批，這是我國首個新冠疫苗專利。

The patent was submitted for application on March 18, and was approved on Aug 11, according to the patent document.
專利文件顯示，該項專利於今年3月18日申請，8月11日獲得授權。

The vaccine, dubbed "Ad5-nCoV", uses a weakened common cold virus to introduce genetic material from the novel coronavirus into the human body. The goal is to train the body to produce antibodies that recognize the coronavirus's spike protein and fight it off.
這款名爲“Ad5-nCoV”的疫苗使用一種減毒普通感冒病毒爲載體，將新冠病毒的遺傳物質傳遞給人體細胞，目的是訓練人體產生能識別並對抗新冠病毒突刺蛋白的抗體。

The phase-two clinical trial of the vaccine has found it is safe and can induce an immune response, according to research published in the journal Lancet last month.
該疫苗的二期臨牀試驗結果於上月發表在《柳葉刀》期刊上，試驗顯示該疫苗安全，且可誘發免疫反應。

The phase-three clinical trial, which will include more participants and be conducted overseas, is currently in the pipeline.
三期臨牀試驗將在海外更多受試者中進行，目前正在推進。